PPARA and renal fibrosis: Indeed, peroxisome proliferator-activated receptor (PPAR) agonists fenofibrate (Kang et al., 2015) and troglitazone (Routh et al., 2002; Weigert et al., 2003), have been approved by FDA to mitigate renal fibrosis, as PPAR signalling promotes fibroblast-mediated ECM degradation (Zhao et al., 2019).